Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Assets (2022 - 2025)

BioXcel Therapeutics has reported Return on Assets over the past 4 years, most recently at 1.45% for Q4 2025.

  • Quarterly results put Return on Assets at 1.45% for Q4 2025, up 38.0% from a year ago — trailing twelve months through Dec 2025 was 1.45% (up 38.0% YoY), and the annual figure for FY2025 was 1.55%, down 13.0%.
  • Return on Assets for Q4 2025 was 1.45% at BioXcel Therapeutics, up from 1.86% in the prior quarter.
  • Over the last five years, Return on Assets for BTAI hit a ceiling of 0.73% in Q4 2022 and a floor of 2.04% in Q2 2025.
  • Median Return on Assets over the past 4 years was 1.73% (2025), compared with a mean of 1.6%.
  • Biggest five-year swings in Return on Assets: tumbled -131bps in 2023 and later surged 38bps in 2025.
  • BioXcel Therapeutics' Return on Assets stood at 0.73% in 2022, then tumbled by -180bps to 2.04% in 2023, then rose by 10bps to 1.83% in 2024, then rose by 21bps to 1.45% in 2025.
  • The last three reported values for Return on Assets were 1.45% (Q4 2025), 1.86% (Q3 2025), and 2.04% (Q2 2025) per Business Quant data.